D-0444-2024 Class I Terminated

Recalled by AvKARE — Pulaski, TN

FDA drug recall D-0444-2024 was initiated by AvKARE on Mar 28, 2024 and is designated Class I. Reason for recall: Microbial contamination of a non-sterile product: potential Bacillus cereus contamination. The recall status is terminated (terminated Aug 23, 2024). Affected quantity: 153 cartons.

Recall details

Product Type
Drugs
Report Date
Apr 24, 2024
Initiation Date
Mar 28, 2024
Termination Date
Aug 23, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
153 cartons

Product description

Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478, NDC 50268-086-12.

Reason for recall

Microbial contamination of a non-sterile product: potential Bacillus cereus contamination.

Distribution pattern

US Nationwide.

Code information

Lot: AW0221A Exp. 08/30/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0444-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0444-2024. Report a data issue: hello@regdatalab.com.